Related Experiment Video
Updated: May 22, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
The role of IMiDs alone or in combination in prostate cancer
Chadi Nabhan1, Daniel P Petrylak
1Department of Medicine, Division of Hematology/Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA. cnabhan@oncmed.net
Abstract:
Recent insights into mechanisms by which prostate cancer becomes castration resistant have allowed better and more rational therapeutic design. These novel therapies have complemented the modest success that chemotherapy has shown in recent years changing the landscape of this disease and leading to improved outcomes. Angiogenesis and immune deregulation are 2 pathways that have increasingly been shown to lead into castration resistant prostate cancer (CRPC). Thalidmide and lenalidomide are immunomodulatory agents with antiangiogenesis properties that have shown activity in this setting with acceptable safety profile. In this review, we discuss briefly the different mechanisms that render prostate cancer castration resistant and elaborate on thalidomide and lenalidomide data in CRPC after reviewing their theoretic mechanisms of action. This timely review coincides with the identification of newer therapies against CRPC affirming our steady movement toward better disease control.
Insights
Newer therapies targeting angiogenesis and immune deregulation offer improved outcomes for castration-resistant prostate cancer (CRPC). Thalidomide and lenalidomide show promise in managing this advanced stage of prostate cancer.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Prostate cancer progression to castration resistance involves angiogenesis and immune deregulation.
- Chemotherapy offers modest success, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review mechanisms of castration-resistant prostate cancer (CRPC) development.
- To elaborate on the efficacy and safety of thalidomide and lenalidomide in CRPC.
Main Methods:
- Review of existing literature on CRPC mechanisms.
- Analysis of clinical data for thalidomide and lenalidomide in CRPC patients.
Main Results:
- Thalidomide and lenalidomide demonstrate activity in CRPC.
- These agents possess immunomodulatory and antiangiogenic properties.
- An acceptable safety profile was observed with these agents.
Conclusions:
- Understanding CRPC mechanisms facilitates rational therapeutic design.
- Thalidomide and lenalidomide represent valuable additions to the CRPC treatment landscape.
- Advancements in CRPC therapies indicate progress toward better disease control.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle